Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Suggested remit: To appraise the clinical and cost effectiveness of sebetralstat within its marketing authorisation for treating acute attacks of hereditary angioedema.

Following on from advice received from the company, NICE has decided to suspend this appraisal from its work programme whilst the company confirm their regulatory filing plans. As this appraisal has ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...

Glofitamab with gemcitabine and oxaliplatin for treating relapsed or refractory diffuse B-cell lymphoma ID6202 Technology appraisal guidance TBC Guselkumab for previously treated moderately to ...

For information, the company have announced that Tecentriq did not meet its primary endpoint during the Phase 3 trial and therefore they will no longer be pursuing a Marketing Authorisation ...

12 SQ-HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280] Technology appraisal guidance 12 February 2025 Abaloparatide for treating ...

Sebetralstat for treating acute attacks of hereditary angioedema in people aged 12 and over ID6284 Technology appraisal guidance TBC Secukinumab for treating enthesitis-related arthritis or juvenile ...

Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ] Technology appraisal guidance Timrepigene emparvovec for treating choroideremia [ID3916] Technology appraisal ...

22 November 2022 Scope consultation end date extended by one week from 24/11/2022 until 01/12/2022. For further information on the guideline development process, please see how we develop NICE ...

Tenecteplase for treating acute ischaemic stroke [ID6306] Technology appraisal guidance 24 July 2024 Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of ...

Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in ...